SRSudha Ravishankar

Sudha Ravishankar

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Sudha Ravishankar has a total of 54 co-authors. Here are the top co-authors by number of shared publications:

  • Vasan K. Sambandamurthy

    Innovative Medicines, AstraZeneca India Pvt. Ltd., Bangalore 560024, India

    4 shared publications
  • Anisha Ambady

    AstraZeneca India Pvt Ltd, Bellary Road, Hebbal, Bengaluru, 560024, India

    3 shared publications
  • Gayathri Balakrishnan

    Innovative Medicines, AstraZeneca India Pvt. Ltd., Bangalore 560024, India

    2 shared publications
  • Naina Vinay Mudugal

    AstraZeneca India Pvt. Ltd., Bellary Road, Hebbal, Bangalore 560024, India

    2 shared publications
  • Sreevalli Sharma

    Innovative Medicines, AstraZeneca India Pvt. Ltd., Bangalore 560024, India

    2 shared publications
  • Sudha Ramaiah

    School of Biosciences & Technology, VIT University, Vellore, 632014, India

    2 shared publications

Latest Publications

  • Scaffold morphing leading to evolution of 2,4-diaminoquinolines and aminopyrazolopyrimidines as inhibitors of the ATP synthesis pathway

    by Subramanyam J. Tantry, Vikas Shinde, Gayathri Balakrishnan, Shankar D. Markad, Amit K. Gupta, Jyothi Bhat, Ashwini Narayan, Anandkumar Raichurkar, Lalit Kumar Jena, Sreevalli Sharma, et al.

    The success of bedaquiline as an anti-tubercular agent for the treatment of multidrug-resistant tuberculosis has validated the ATP synthesis pathway and in particular ATP synthase as an attractive target. However, limitations associated with its use in the clinic and the drug–drug interactions with rifampicin have prompted research efforts towards identifying alternative ATP synthesis inhibitors with differentiated mechanisms of action. A biochemical assay was employed to screen AstraZeneca's corporate compound collection to identify the inhibitors of mycobacterial ATP synthesis. The high-throughput screening resulted in the identification of 2,4-diaminoquinazolines as inhibitors of the ATP synthesis pathway. A structure–activity relationship for the quinazolines was established and the knowledge was utilized to morph the quinazoline core into quinoline and pyrazolopyrimidine to expand the scope of chemical diversity. The morphed scaffolds exhibited a 10-fold improvement in enzyme potency and over 100-fold improvement in selectivity against inhibition of mammalian mitochondrial ATP synthesis. These novel compounds were bactericidal and demonstrated growth retardation of Mycobacterium tuberculosis in the acute mouse model of tuberculosis infection.


  • Open Access

    Essentiality Assessment of Cysteinyl and Lysyl-tRNA Synthetases of Mycobacterium smegmatis

    by Sudha Ravishankar, Anisha Ambady, Rayapadi G. Swetha, Anand Anbarasu, Sudha Ramaiah, Vasan K. Sambandamurthy

    Discovery of mupirocin, an antibiotic that targets isoleucyl-tRNA synthetase, established aminoacyl-tRNA synthetase as an attractive target for the discovery of novel antibacterial agents. Despite a high degree of similarity between the bacterial and human aminoacyl-tRNA synthetases, the selectivity observed with mupirocin triggered the possibility of targeting other aminoacyl-tRNA synthetases as potential drug targets. These enzymes catalyse the condensation of a specific amino acid to its cognate tRNA in an energy-dependent reaction. Therefore, each organism is expected to encode at least twenty aminoacyl-tRNA synthetases, one for each amino acid. However, a bioinformatics search for genes encoding aminoacyl-tRNA synthetases from Mycobacterium smegmatis returned multiple genes for glutamyl (GluRS), cysteinyl (CysRS), prolyl (ProRS) and lysyl (LysRS) tRNA synthetases. The pathogenic mycobacteria, namely, Mycobacterium tuberculosis and Mycobacterium leprae, were also found to possess two genes each for CysRS and LysRS. A similar search indicated the presence of additional genes for LysRS in gram negative bacteria as well. Herein, we describe sequence and structural analysis of the additional aminoacyl-tRNA synthetase genes found in M. smegmatis. Characterization of conditional expression strains of Cysteinyl and Lysyl-tRNA synthetases generated in M. smegmatis revealed that the canonical aminoacyl-tRNA synthetase are essential, while the additional ones are not essential for the growth of M. smegmatis.


  • Genetic and chemical validation identifies Mycobacterium tuberculosis topoisomerase I as an attractive anti-tubercular target

    by Sudha Ravishankar, Anisha Ambady, Disha Awasthy, Naina Vinay Mudugal, Sreenivasaiah Menasinakai, Sandesh Jatheendranath, Supreeth Guptha, Sreevalli Sharma, Gayathri Balakrishnan, Radha Nandishaiah, et al.


  • Open Access

    An IPTG Inducible Conditional Expression System for Mycobacteria

    by Sudha Ravishankar, Anisha Ambady, Haripriya Ramu, Naina Vinay Mudugal, Ragadeepthi Tunduguru, Anand Anbarasu, Umender K. Sharma, Vasan K. Sambandamurthy, Sudha Ramaiah

    Conditional expression strains serve as a valuable tool to study the essentiality and to establish the vulnerability of a target under investigation in a drug discovery program. While essentiality implies an absolute requirement of a target function, vulnerability provides valuable information on the extent to which a target function needs to be depleted to achieve bacterial growth inhibition followed by cell death. The critical feature of an ideal conditional expression system is its ability to tightly regulate gene expression to achieve the full spectrum spanning from a high level of expression in order to support growth and near zero level of expression to mimic conditions of gene knockout. A number of bacterial conditional expression systems have been reported for use in mycobacteria. The utility of an isopropylthiogalactoside (IPTG) inducible system in mycobacteria has been reported for protein overexpression and anti-sense gene expression from a replicating multi-copy plasmid. Herein, we report the development of a versatile set of non-replicating IPTG inducible vectors for mycobacteria which can be used for generation of conditional expression strains through homologous recombination. The role of a single lac operator versus a double lac operator to regulate gene expression was evaluated by monitoring the expression levels of β-galactosidase in Mycobacterium smegmatis. These studies indicated a significant level of leaky expression from the vector with a single lac operator but none from the vector with double lac operator. The significance of the double lac operator vector for target validation was established by monitoring the growth kinetics of an inhA, a rpoB and a ftsZ conditional expression strain grown in the presence of different concentrations of IPTG. The utility of this inducible system in identifying target specific inhibitors was established by screening a focussed library of small molecules using an inhA and a rpoB conditional expression strain.